These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34922020)

  • 1. Achieving end-to-end success in the clinic: Pfizer's learnings on R&D productivity.
    Fernando K; Menon S; Jansen K; Naik P; Nucci G; Roberts J; Wu SS; Dolsten M
    Drug Discov Today; 2022 Mar; 27(3):697-704. PubMed ID: 34922020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reviving an R&D pipeline: a step change in the Phase II success rate.
    Wu SS; Fernando K; Allerton C; Jansen KU; Vincent MS; Dolsten M
    Drug Discov Today; 2021 Feb; 26(2):308-314. PubMed ID: 33129994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The journey of a lifetime - development of Pfizer's COVID-19 vaccine.
    Thorn CR; Sharma D; Combs R; Bhujbal S; Romine J; Zheng X; Sunasara K; Badkar A
    Curr Opin Biotechnol; 2022 Dec; 78():102803. PubMed ID: 36162187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Race to Develop the Pfizer-BioNTech COVID-19 Vaccine: From the Pharmaceutical Scientists' Perspective.
    Lewis LM; Badkar AV; Cirelli D; Combs R; Lerch TF
    J Pharm Sci; 2023 Mar; 112(3):640-647. PubMed ID: 36130677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States.
    Di Fusco M; Marczell K; Deger KA; Moran MM; Wiemken TL; Cane A; de Boisvilliers S; Yang J; Vaghela S; Roiz J
    J Med Econ; 2022; 25(1):605-617. PubMed ID: 35574613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation for mass vaccination against COVID-19.
    Wang WC; Fann JC; Chang RE; Jeng YC; Hsu CY; Chen HH; Liu JT; Yen AM
    J Formos Med Assoc; 2021 Jun; 120 Suppl 1():S95-S105. PubMed ID: 34108119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study.
    Iwamoto M; Ukimura A; Ogawa T; Kawanishi F; Osaka N; Kubota M; Mori T; Sawamura R; Nishihara M; Suzuki T; Uchiyama K
    PLoS One; 2022; 17(5):e0268529. PubMed ID: 35576209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixing the Achilles Heel of Pfizer's Paxlovid for COVID-19 Treatment.
    Brewitz L; Schofield CJ
    J Med Chem; 2024 Jul; 67(14):11656-11661. PubMed ID: 38967233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pfizer's small-molecule antiviral misses on COVID prevention.
    Mullard A
    Nat Rev Drug Discov; 2022 Jun; 21(6):406. PubMed ID: 35538236
    [No Abstract]   [Full Text] [Related]  

  • 10. Covid-19: Campaign takes on Pfizer's "profiteering".
    Shepherd A
    BMJ; 2022 May; 377():o1111. PubMed ID: 35504624
    [No Abstract]   [Full Text] [Related]  

  • 11. The costs of coronavirus vaccines and their pricing.
    Light DW; Lexchin J
    J R Soc Med; 2021 Nov; 114(11):502-504. PubMed ID: 34732097
    [No Abstract]   [Full Text] [Related]  

  • 12. Acquiring Pharmaceutical Industry Assets in the UK: 1 + 1 = 1?
    Kanavos P; Angelis A
    Pharmaceut Med; 2014; 28(5):245-248. PubMed ID: 25346596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.
    Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A
    BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biopharma dealmaking in 2020.
    Giglio P; Micklus A
    Nat Rev Drug Discov; 2021 Feb; 20(2):95-96. PubMed ID: 33446884
    [No Abstract]   [Full Text] [Related]  

  • 16. How to improve R&D productivity: the pharmaceutical industry's grand challenge.
    Paul SM; Mytelka DS; Dunwiddie CT; Persinger CC; Munos BH; Lindborg SR; Schacht AL
    Nat Rev Drug Discov; 2010 Mar; 9(3):203-14. PubMed ID: 20168317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incentivising wealthy nations to participate in the COVID-19 Vaccine Global Access Facility (COVAX): a game theory perspective.
    McAdams D; McDade KK; Ogbuoji O; Johnson M; Dixit S; Yamey G
    BMJ Glob Health; 2020 Nov; 5(11):. PubMed ID: 33257418
    [No Abstract]   [Full Text] [Related]  

  • 18. Covid-19: an economic perspective on vaccinating the world.
    Donaldson C; Biosca O
    BMJ; 2021 Jun; 373():n1498. PubMed ID: 34130993
    [No Abstract]   [Full Text] [Related]  

  • 19. Discovery and development of COVID-19 vaccines and therapeutics: nonclinical perspectives.
    Khan N; Sathish J; Rohde CM
    J Toxicol Sci; 2024; 49(3):79-94. PubMed ID: 38432955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R&D productivity rides again?
    Lendrem D; Senn SJ; Lendrem BC; Isaacs JD
    Pharm Stat; 2015; 14(1):1-3. PubMed ID: 25336017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.